By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteome Sciences said today that it has signed a non-exclusive license with Randox Laboratories for use of its stroke protein biomarker portfolio.

Randox will use the markers in products for early diagnosis of stroke and subsequent patient monitoring. The agreement provides Proteome Sciences with "seven-digit (US dollar) license and development milestones" as well as double-digit royalties on sales, the London, UK-based company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.